HK inno.N Corporation (KOSDAQ:195940)

Market Cap	1.16T +2.2%
Revenue (ttm)	839.63B +12.9%
Net Income	41.49B +58.1%
EPS	1,451.65 +96.5%
Shares Out	28.33M
PE Ratio	28.31
Forward PE	11.92
Dividend	350.00 (0.90%)
Ex-Dividend Date	Mar 30, 2026

Volume	207,074
Open	39,100
Previous Close	39,000
Day's Range	38,800 - 43,000
52-Week Range	37,300 - 58,600
Beta	0.52
Analysts	Buy
Price Target	68,916.67 (+67.68%)
Earnings Date	Jul 28, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1984
• Employees: 1,695
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.

Analyst Summary

According to 12 analysts, the average rating for 195940 stock is "Buy." The 12-month stock price target is ₩68,917, which is an increase of 67.68% from the latest price.

Price Target

₩68,917

(67.68% upside)

Analyst Consensus: Buy